TheBateman schreef op 27 november 2017 00:23:
The Group directors concluded that the significant influence over its TiGenix investment has
ceased. The facts that lead to that conclusion are the resignation of its preferred rights to
distribute the main drug under investigation by TiGenix and the fact that Grifols Group has no
longer appointed board members and do not expect to have any. Additionally it has been
considered the fact that the time needed for exercising its right of appointment of one board
director is too long as to allow Grifols to participate in the board decisions in due time.
As a consequence the investment in TiGenix has been reclassified to Available for Sale Financial
Assets. The effect of this reclassification resulted in a revaluation of the investment at fair value
and the related gain amounting to Euros 24 million has been accounted for in Share of